GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
(Full) agonists are able to activate the receptor and result in a strong biological response. The natural endogenous ligand with the greatest efficacy for a given receptor is by definition a full agonist (100% efficacy). Partial agonists do not activate receptors with maximal efficacy, even with maximal binding, causing partial responses compared to those of full agonists (efficacy between 0 and 100%). Antagonists bind to receptors but do not activate them. This results in a receptor blockade, inhibiting the binding of agonists and inverse agonists. Receptor antagonists can be competitive (or reversible), and compete with the agonist for the receptor, or they can be irreversible antagonists that form covalent bonds (or extremely high affinity non-covalent bonds) with the receptor and completely block it. The proton pump inhibitor omeprazole is an example of an irreversible antagonist. The effects of irreversible antagonism can only be reversed by synthesis of new receptors. Inverse agonists reduce the activity of receptors by inhibiting their constitutive activity (negative efficacy). Allosteric modulators: They do not bind to the agonist-binding site of the receptor but instead on specific allosteric binding sites, through which they modify the effect of the agonist. For example, benzodiazepines (BZDs) bind to the BZD site on the GABAA receptor and potentiate the effect of endogenous GABA. Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects.
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
Most commercial 99Mo/99mTc generators use column chromatography, in which 99Mo in the form of water-soluble molybdate, MoO42− is adsorbed onto acid alumina (Al2O3). When the 99Mo decays, it forms pertechnetate TcO4−, which, because of its single charge, is less tightly bound to the alumina. Pulling normal saline solution through the column of immobilized 99MoO42− elutes the soluble 99mTcO4−, resulting in a saline solution containing the 99mTc as the dissolved sodium salt of the pertechnetate. One technetium-99m generator, holding only a few micrograms of 99Mo, can potentially diagnose 10,000 patients because it will be producing 99mTc strongly for over a week.
{\displaystyle {\frac {D{\boldsymbol {\omega }}}{Dt}}={\frac {\partial {\boldsymbol {\omega }}}{\partial t}}+(\mathbf {u} \cdot \nabla ){\boldsymbol {\omega }}=({\boldsymbol {\omega }}\cdot \nabla )\mathbf {u} }
Sources: en.wikipedia.org
=== Marrow fat cells === Marrow adipocytes are unilocular like white fat cells. The marrow adipose tissue depot is poorly understood in terms of its physiologic function and relevance to bone health. Marrow adipose tissue expands in states of low bone density but additionally expands in the setting of obesity. Marrow adipose tissue response to exercise approximates that of white adipose tissue. Exercise reduces both adipocyte size as well as marrow adipose tissue volume, as quantified by MRI or μCT imaging of bone stained with the lipid binder osmium.
Specifically when set up in a loop with a buffering liquid between the incoming and outgoing fluid running in a circuit, and with active transport pumps on the outgoing fluid's tubes, the system is called a countercurrent multiplier, enabling a multiplied effect of many small pumps to gradually build up a large concentration in the buffer liquid. Other countercurrent exchange circuits where the incoming and outgoing fluids touch each other are used for retaining a high concentration of a dissolved substance or for retaining heat, or for allowing the external buildup of the heat or concentration at one point in the system. Countercurrent exchange circuits or loops are found extensively in nature, specifically in biologic systems. In vertebrates, they are called a rete mirabile, originally the name of an organ in fish gills for absorbing oxygen from the water. It is mimicked in industrial systems. Countercurrent exchange is a key concept in chemical engineering thermodynamics and manufacturing processes, for example in extracting sucrose from sugar beet roots. Countercurrent multiplication is a similar but different concept where liquid moves in a loop followed by a long length of movement in opposite directions with an intermediate zone. The tube leading to the loop passively building up a gradient of heat (or cooling) or solvent concentration while the returning tube has a constant small pumping action all along it, so that a gradual intensification of the heat or concentration is created towards the loop.
Marlowe (1988), creator of Castle; writer of Air Force One, End of Days, and Hollow Man Lawrence Trilling (1988), showrunner of Parenthood and Goliath Maiken Baird (1989), documentary film producer, Client 9: The Rise and Fall of Eliot Spitzer Sam Bisbee (1990), Emmy Award-winning producer and composer Gina Fattore (1990), producer and writer of Dawson's Creek, Gilmore Girls, Parenthood, creator of Dare Me Jeff Rake (1990), television producer, writer of Boston Legal and creator of Manifest and The Mysteries of Laura Dede Gardner (1990), Academy Award-winning producer of 12 Years a Slave; president of Plan B Entertainment Jenji Kohan (1991), television writer, producer, creator of Orange Is the New Black and Weeds Ari Gold (1992), filmmaker, director of Adventures of Power Elizabeth Craft (1993), producer, screenwriter, Fantasy Island, The 100, Lie to Me Ethan McSweeny (1993), former artistic director of the American Shakespeare Center, recipient of a 2018 Helen Hayes Award Brian Yorkey (1993), playwright, co-winner of the 2010 Pulitzer Prize for Drama for writing the musical Next to Normal Anna Winger (1993), screenwriter, creator of miniseries Deutschland 83, Deutschland 86, and Unorthodox Imara Jones (1994), political journalist and director Nicole Kassell (1994), director and producer of Watchmen, winner of the 2020 Directors Guild of America Award for Outstanding Directing – Drama Series Tim Carvell (1995), head writer of The Daily Show and executive producer of Last Week Tonight with John Oliver Josh Fox (1995), Academy Award-nominated documentary director, Gasland Adam Egypt Mortimer (1995), director of Daniel Isn't Real, Archenemy Henry Alex Rubin (1995), Academy Award-nominated director, Murderball Julius Sharpe (1995), television writer and showrunner of Making History and United We Fall Ramin Bahrani (1996), writer-director of Man Push Cart, Chop Shop and Fahrenheit 451, 2021 Academy Award for Best Adapted Screenplay nominee Moira Demos (1996), filmmaker who produced Netflix documentary Making a Murderer Yana Gorskaya (1996), Academy Award-nominated film editor, Spellbound Cetywa Powell (1996), director and fine art photographer Courtney Lilly (1997), television producer, showrunner of Black-ish, Grown-ish, Mixed-ish Nancy Schwartzman (1997), director, Roll Red Roll Beau Willimon (1999), creator and producer of House of Cards; writer of the play Farragut North Vikram Gandhi (2000), director, Kumaré, Barry, reporter for Vice Andrew Goldberg (2000), creator of Netflix series Big Mouth Ned Benson (2001), director, The Disappearance of Eleanor Rigby Dan Harris (2001), Saturn Award-winning screenwriter, X2, Superman Returns; director, Imaginary Heroes Andrew Neel (2001), filmmaker, director of King Kelly, Goat Anna Boden (2002), co-writer of Half Nelson and director of Sugar, Captain Marvel Tze Chun (2002), award-winning director, Children of Invention Lang Fisher (2002), co-creator of Never Have I Ever, writer of 30 Rock and Brooklyn Nine-Nine, Peabody Award winner in 2008 Susanna Fogel (2002), Emmy Award and BAFTA Award-nominated director Will Graham (2002), creator of the Onion News Network, showrunner of Mozart in the Jungle, Peabody Award winner in 2008 Ashley Lyle (2002), screenwriter, showrunner of Yellowjackets Justin Marks (2002), screenwriter, The Jungle Book, Counterpart Katori Hall (2003), playwright, The Mountaintop, winner of the 2021 Pulitzer Prize for Drama Raamla Mohamed (2003), Emmy Award-nominated screenwriter, Little Fires Everywhere Graham Moore (2003), winner of the 2015 Academy Award for Best Adapted Screenplay for his screenplay of The Imitation Game Lucia Aniello (2004), director of Rough Night and Time Traveling Bong Gabe Liedman (2004), creator of Q-Force, writer of Brooklyn Nine-Nine, PEN15, Inside Amy Schumer and Kroll Show Zhang Mo (2005), Chinese director, daughter of Zhang Yimou Laura Goode (2006), author, columnist, and producer of Farah Goes Bang Matt Kaplan (2006), producer of young adult films, To All the Boys franchise Meera Menon (2006), Indian-American director, Equity Lilly Burns (2009), television producer, co-founder of Jax Media and president of Imagine Entertainment Eli Bush (2009), film and theatre producer and winner of the Golden Globe Award in 2018 for Lady Bird Jason Fuchs (2009), actor and screenwriter, Pan, Ice Age: Continental Drift Jessica Kingdon (2009), Academy Award-nominated Chinese-American documentary director Nuotama Bodomo (2010), Ghanaian filmmaker and co-writer of sketch comedy Random Acts of Flyness on HBO Sabaah Folayan (2013), director of documentary Whose Streets?
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。